PFM Health Sciences’s Inhibrx, Inc. Common Stock INBX Stock Holding History

PFM Health Sciences’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-47,918	Closed	-$1.68M	–	96
2024 Q1	$1.68M	Sell	47,918 -490,046	-91%	-$17.9M	0.08%	83
2023 Q4	$20.4M	Buy	537,964 +249,347	+86%	+$5.34M	1.23%	29
2023 Q3	$5.3M	Buy	288,617 +160,914	+126%	+$3.37M	0.25%	64
2023 Q2	$3.32M	Buy	127,703 +6,256	+5%	+$146K	0.13%	74
2023 Q1	$2.29M	Buy	+121,447	New	+$2.82M	0.1%	71

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

PFM Health Sciences's INBX Position: Q2 2024 in Review

PFM Health Sciences sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 47,918 shares — an estimated $1.68M sold.

PFM Health Sciences first reported a position in INBX in Q1 2023 and held it in 5 quarters. The position peaked at $20.4M in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

PFM Health Sciences reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
PFM Health Sciences sold 47,918 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $1.68M.
PFM Health Sciences first reported a position in Inhibrx, Inc. Common Stock in Q1 2023 and held it in 5 quarters.
PFM Health Sciences's Inhibrx, Inc. Common Stock position peaked at $20.4M in Q4 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on PFM Health Sciences's 13F filing for Q2 2024, filed 14 Aug 2024.